FDA Mandates Revised Cardiovascular and Prostate Cancer Risk Information in Testosterone Therapy Labeling

FDA Requires Updated Safety Labeling for Testosterone Replacement Therapy Products

The U.S. Food and Drug Administration has required manufacturers of testosterone replacement therapy products to update product labeling with strengthened information on cardiovascular risks, abuse and dependence potential, pulmonary oil microembolism and anaphylaxis for injectable formulations, and requirements for hematocrit and prostate-specific antigen monitoring. The revisions incorporate clinical evidence from the TRAVERSE randomized trial and postmarketing reports while reiterating that these products are indicated only for hypogonadism of known organic etiology and not for age-related testosterone decline. The changes build on prior FDA actions from 2015 and 2016.

The FDA reviewed contemporary trial data alongside earlier evidence syntheses to inform the standardized safety language.

Timeline of Labeling Requirements

The FDA required updated labeling with strengthened cardiovascular risk information including potential for major adverse cardiovascular events on March 3, 2015 [1]. Labeling instructs prescribers to inform patients of risks and benefits.

On October 25, 2016, the FDA added a boxed warning for abuse and dependence, noting serious outcomes that include heart attack, stroke, liver injury, psychiatric effects, and death [1].

On February 28, 2024, the FDA required that labeling must include warnings for pulmonary oil microembolism and anaphylaxis specific to injectable oil-based testosterone formulations [1].

Clinical Evidence Reviewed

The TRAVERSE trial published June 16, 2023 in the New England Journal of Medicine enrolled 5,246 hypogonadal men and showed no statistically significant increase in major adverse cardiovascular events with testosterone-replacement therapy compared with placebo [2]. The FDA reviewed these findings as part of its ongoing safety assessment.

The National Institutes of Health summarized the evidence synthesis used by U.S. regulatory agencies to inform labeling decisions [4].

International Regulatory Context

The European Medicines Agency conducted a parallel assessment of testosterone-containing medicines and reached risk conclusions that align with FDA actions on individualized benefit-risk evaluation [3].

Both agencies state that testosterone therapy is indicated only for confirmed hypogonadism of organic etiology [3][4].

What this means

The updated labeling integrates TRAVERSE trial results showing no statistically significant increase in major adverse cardiovascular events with prior observational data and case reports that supported existing warnings [2]. FDA documents require standardized communication of cardiovascular, abuse, pulmonary oil microembolism, anaphylaxis, and prostate monitoring information within the approved indications [1]. The revisions specify parameters for hematocrit and prostate-specific antigen monitoring in the prescribing information [1]. These labeling changes apply to approved products and do not extend to off-label uses or compounded testosterone formulations [1][4].

Limitations

Long-term (>5 years) safety data in diverse populations remain limited. Observational studies and trials show heterogeneous results on cardiovascular risk. Causality for certain rare events (e.g., pulmonary oil microembolism) is based on case reports. Labeling changes do not address all off-label uses or compounded testosterone products [4].